UNLIMITED TURBO SHORT - ELI LILLY & CO | Delayed Deutsche Boerse AG 11:50:33 20/06/2024 BST | ||
| 2 EUR | +2.04% |
|
| Current month | -76.18% | ||
| 1 month | -84.24% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 20/06/24 | 2 | +2.04% |
| 19/06/24 | 1.96 | -19.67% |
| 18/06/24 | 2.44 | -8.27% |
| 17/06/24 | 2.66 | -18.40% |
| 14/06/24 | 3.26 | +14.79% |
Delayed Quote Deutsche Boerse AG
Last update June 20, 2024 at 11:50 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PN9SU9 |
| ISIN | DE000PN9SU92 |
| Date issued | 16/10/2023 |
| Strike | 904.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 27.46 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 33.64 € |
|---|---|
| Lowest since issue | 1.8 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
891.5
USD
Average target price
855.4
USD
Spread / Average Target
-4.05%
- Stock Market
- Certificates
- Certificat
